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Abstract  
 
Bioceramics, natural and synthetic, are designed to induce a strong bonding to bone and appeared 
as an alternative to metallic implants. Bioceramic materials currently used for the repair and 
reconstruction of hard and soft tissues can be categorized according its composition, structure, and 
properties. These biomaterials are grouped bioinert ceramics as alumina and zirconia, bioactive 
glasses and glass ceramics and bioresorbable calcium phosphates-based materials. The 
bioceramics concepts, namely physico-chemical, mechanical and biological properties, and 
respective applications in diverse fields of tissue engineering are discussed in depth herein. An up-
to-date of bioceramics clinical trials is also considered. Based on the stringent requirements for 
clinical application, prospects for the development of advanced functional bioceramics for tissue 
engineering are highlighted for the future. 
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4.1 INTRODUCTION 
Bioceramics, natural or synthetic origin, are a class of inorganic and non-metallic ceramics used 
for repair and regeneration of diseased and damaged parts of the musculoskeletal system and 
periodontal anomalies. These ceramic materials have been developed for orthopedic load-bearing 
coatings (hip acetabular cups), bone grafts and cements, and dental implants (1). Bioceramics are 
typically characterized by their excellent biocompatibility, osteoconductivity, corrosion resistance, 
and a hard brittle surface. Weaknesses of bioceramics include poor fracture toughness, brittleness, 
very low elasticity and extremely high stiffness (2). Consequently, their clinical applications for 
tissue engineering (TE) has been limited. In general, bioceramics are classified as: 
 Bioinert: has no interaction with its surrounding tissue after implantation. They have a 
reasonable fracture toughness, and resistance to corrosion and wear. These ceramics are 
typically used as structural-support implants, such as bone devices and femoral head. 
Examples of bioinert ceramics are alumina and zirconia. 
 Bioactive: bond directly with living tissues after implantation, with the pattern of bonding 
osteogenesis. These ceramics are brittle and has been applied for the filling of small bone 
defects and periodontal irregularities. Examples are bioglasses and glass-ceramics. 
 Bioresorbable: gradually absorbed in vivo and is replaced by bone over time. Examples are 
calcium phosphates (CaPs), calcium phosphate cements (CPCs), and calcium carbonates or 
calcium silicates.  
 
Current efforts center considerable attention in TE involving bioceramics for developing 3D-based 
scaffolds able to mimic the structural, mechanical and biological properties of natural tissues (3, 
4). Moreover, to stimulate cells differentiation and extracellular matrix (ECM) production during 
the regeneration process, are also important issues to be considered envisioning the formation of 
new tissues. Bioceramics are stronger under compression and weak under tension and these facts 
need to be contemplated when fabricating scaffolds for particular biomedical application. These 
structures hold porous and fibrous scaffolds, and hydrogels, with defined architecture, controlled 
degradation rate, and optimized porosity and pore interconnectivity. Scaffold fabrication 
techniques include sponge replica method, solvent casting and particulate-leaching, freeze drying, 
gas foaming and phase separation, rapid prototyping and electrospinning (4-11). The latter two 
ones are extremely attractive in their ability to mimic new tissue structures and with the possibility 
of incorporating pharmaceutical agents, even though are expensive and suffer from the materials 
choice and costs. Additionally, additive manufacturing such as bioprinting and bioinks have 
presenting a high potential in combination with the design and imaging techniques bringing 
innovations at the micro- and nano-scale to regenerative medicine (12).  
An array of natural and synthetic bioceramics has been proposed to be used in the processing TE 
scaffolding with specific composition, microstructure and long-term reproducibility. Bioceramics 
from natural origin, such as corals, nacres, sponges, and animal (fish and chicken) bones, also 
provide an abundant source of calcium compounds (e.g., calcium carbonate and calcium 
phosphate) for skeletal TE applications (13). Coral-derived materials has been widely used as raw 
materials to preparing CaPs biomaterials for bone tissue regeneration, due to their unique 
microstructural composition and mechanical properties. Our group has been proposing a variety 
of red algae (e.g., Coralline officinallis) to produce porous ceramics aiming bone repair and 
regeneration (14, 15). This process involves the conversion of calcium carbonate skeletons of C. 
officinallis particulates into CaPs with hydroxyapatite (HA) nanocrystallites, while maintaining 
the native microstructure of the red algae, using a thermal and chemical treatment (14). 
Concerning synthetic bioceramics, alumina and zirconia, bioactive porous glasses and glass-
ceramics, and CaPs-based materials in the form of sintered ceramics, coatings and cement pastes, 
are the ones mostly used in TE applications (16, 17). These bioceramics can be prepared by several 
methods (e.g. wet precipitation, hydrolysis, sol-gel synthesis, hydrothermal synthesis, 
mechanochemical synthesis,  microwave processing, or spray drying methods) yielding materials 
with different properties, such as crystal size and morphology. Among them, wet precipitation 
method has the advantage on the homogeneity of the final product, and the easiness of controlling 
parameters (e.g. temperature, pH, and the presence of additives) during synthesis (18).  
Many studies are dedicated on bioceramic materials incorporating ionic elements (e.g. strontium, 
zinc, magnesium, manganese, silicon) that would be released during bone graft resorption, and 
hence can influence bone health and enhance biocompatibility, while strengthening the mechanical 
properties of the implants (19-23). Besides, minerals and traces of metal elements may provide 
physicochemical modifications in the produced materials, which can accelerate bone formation 
and resorption in vivo (24, 25). 
This chapter aims at presenting a concise and reachable overview of bioceramics for applications 
in the contexts of musculoskeletal and periodontal tissue regeneration. A range of materials are 
considered, from bioinert to bioactive and bioresorbable bioceramics. Particularly, emphasis is set 
on synthetic bioceramics physicochemical, mechanical and biological properties. Clinical trials 
involving bioceramics, challenges and future prospects of research in this field are also underlined. 
 
 
4.2 BIOCERAMIC MATERIALS CONCEPTS 
  
4.2.1 Alumina and Zirconia 
Alumina (Al2O3) and Zirconia (ZrO2) are well known for their general chemical inertness, high 
strength, hardness, cracking, and corrosion resistance, thus being recognized as bioinert ceramics 
successfully used in orthopedics, specifically for total hip/knee arthroplasty, and in dental 
repair/replacement (Figure 1) (26, 27).  
Alumina-based bioceramics were the first commercially available for dental implantation and 
acetabular cup replacement in total hip prostheses (28). Alumina favorably combine high hardness 
and high abrasion resistance, associated with its surface energy and smoothness. Hence, this 
bioceramic has been used as synthetic bone grafts or as porous prosthetic device, by using a 
biomimetic coating on alumina in order to provide a stable bond with the host tissue. Further 
clinical applications of alumina prostheses include bone screws, alveolar ridge (jaw bone) and 
maxillofacial reconstruction, ossicular (middle ear) bone substitutes, corneal replacements, 
segmental bone replacements, and blade and screw and post-type dental implants (29). However, 
the alumina ceramics have low fracture toughness, which can be signiﬁcantly improved by adding 
zirconia (known as zirconia-toughened alumina (ZTA) or alumina-toughened zirconia (ATZ)) 
resulting in a composite material with enhanced toughness and tribological properties (30, 31). 
ZTA comprises alumina (70–95%) matrix phase and zirconia polycrystals (TZP) (5-30%) as the 
secondary phase, thus combining the advantageous properties of monolithic alumina and zirconia. 
In addition, the wear properties and low susceptibility to stress-assisted degradation of alumina 
ceramics is also preserved in ZTA ceramics, reducing the risk of impingement and dislocation, 
and improving stability (31). 
In consequence of its polymorphic crystalline structure – monoclinic, tetragonal, and cubic - 
zirconia-based bioceramics, namely tetragonal TZP, have been widely popular in bone TE, due to 
their excellent fracture toughness, high strength, elastic modulus, and wear resistance (32). For 
example, partially stabilized zirconia (with yttria, CaO, and MgO) materials are known to have 
flexural strength above 1,000 MPa and fracture toughness higher than 8 MPam1/2 (33, 34). Besides 
its mechanical properties, zirconia promotes cell proliferation and differentiation in osteogenic 
pathways, as well as osseointegration, and has radiopaqueness that helps the monitoring in 
radiographs (35). Zirconia has often been used in dentistry since it has the advantage of being 
coloured to match the shade of any existing teeth. 
 
 FIGURE 1. Examples of alumina/zirconia bioceramics for hip joint prosthesis and dentistry (36, 
37). 
 
4.2.2 Bioactive glasses and glass-ceramics 
Bioactive glasses and glass–ceramics have been developed for TE applications, in both orthopedic 
and dental field, in dense and porous form (Figure 2) (38-40). Glass-ceramics are crystallized 
glasses resultant from thermal treatment of its parent glasses, with superior strength and toughness, 
elastic modulus, and wear resistance.  
Bioactive glasses have unique properties with ability to bond to both hard and soft connective 
tissues more rapidly than other bioceramics, converting into an amorphous calcium phosphate or 
hydroxyapatite material after implantation. Moreover, it is also reported that the ions Si, Ca, P and 
Na, released during dissolution of certain bioactive glasses compositions appear to activate 
expression of osteogenic genes, and to stimulate neovascularisation and angiogenesis, enzymatic 
activity, and differentiation of mesenchymal stem cells (MSCs) (41-43).  
The pioneering work in the field of bioactive glasses, for biomedical applications, data from the 
beginning of the 1970s with the development of 45S5 Bioglass  by Larry Hench (29). Bioglass, 
is a silica-based bioactive glass in the Na2O-CaO-SiO2-P2O5 system with a composition close to a 
ternary eutectic in the Na2O–CaO–SiO2 diagram. This type of glass has also the particularity of 
stimulates bone growth away from the bone–implant interface, which mechanism can be attributed 
to a hydroxycarbonate apatite layer on the surface of the glass (40, 44, 45).  
Besides silicate glasses, phosphate-based and borate-based glasses are other types of bioactive 
glasses developed for biomedical use. Phosphate bioactive glasses, in the Na2O-CaO-P2O5 system, 
have faster dissolution in aqueous fluids, than that for silica glasses, useful in the healing of chronic 
wounds and as carriers in drug delivery such as antibacterial ions and complex organic molecules 
for chemotherapy applications (46, 47). By its turn, borate-based glasses, in the B2O3-Na2O-CaO-
P2O5 system, have fast degradation rates and are able to completely convert into apatite when 
immersed in an aqueous phosphate solution following a similar process of Bioglass, but without 
the formation of a silica-rich layer (48, 49). Borate glasses have been also used as drug release 
systems in the treatment of bone infection (50). A concern associated with these type of glasses is 
the toxicity of boron released into the solution as borate ions, which can be reduced in in vitro 
dynamic culture conditions (51). 
The common methods of synthesis of bioactive glasses include conventional melt-quenching, sol-
gel process, flame synthesis and microwave irradiation (52, 53).   
 
 
 
FIGURE 2. Bioactive glass and glass-ceramics for biomedical applications and porous robocast 
bioglass produced at Missouri University of Science and Technology for bone repair and 
regeneration (*) (54, 55). 
 
 
4.2.3 Calcium phosphates 
Calcium phosphates (CaPs) are the chemical compounds of special interest for TE applications 
due to their close resemblance with the inorganic part of major normal and pathological calcified 
tissues of mammals (56-58). These types of bioceramics hold an outstanding biological 
performance, such as biocompatibility, osteoconductivity and bioresorbability, thus integrating 
into living tissue by the same processes active in bone remodeling. Besides, CaPs are easy to 
produce with a low cost, and can be relatively easily certified as medical grade. Despite that, CaPs 
are limited to load-bearing applications due to their poor mechanical properties, namely, strength 
and fatigue resistance, being primarily used as fillers and coatings in the biomedical field (56, 59). 
However, CaPs bioceramics are also available in particles, dense or porous blocks, injectable 
compositions, implant coatings, and composites with polymers (Figure 3). Custom-designed forms 
as wedges for tibial opening osteotomy, cones for spine and knee, and inserts for vertebral cage 
fusion, are also available. CaPs are used in alveolar ridge augmentation, tooth replacement, 
maxillofacial reconstruction, orbital implants, increment of the hearing ossicles, spine fusion and 
repair of bone defects (60).  
 
 
FIGURE 3.   Commercial calcium phosphate-based bone graft materials, such as porous blocks, 
powders and granules, and HA coating on femoral metal stem. Reprinted from Ref. (57), with 
permission.  
 
 
 
The most known CaPs, listed in Table 1.1, comprise Ca/P molar ratios in the range of 0.5 - 2, 
depending on their acidity and solubility. CaP is more acidic and water-soluble for lower Ca/P 
molar ratios (61). The majority of CaPs are sparingly soluble in water, but, all of them are easily 
soluble in acids but insoluble in alkaline solutions. According to solubility, CaPs can be ranked in 
order of increasing the in situ degradation rate as: MCPM > TTCP  α-TCP > DCPD > OCP > β-
TCP > HA. 
 
Table 1.1: Main calcium phosphates used for biomedical applications (3, 57). 
Calcium 
phosphate 
Formula 
Ca/P 
molar 
ratio 
pH stability 
range in 
aqueous 
solutions at 
25°C 
Properties 
Monocalcium 
phosphate 
monohydrate 
(MCPM) 
Ca(H2PO4)2.H2O 0.5 0.0 – 2.0 
Not biocompatible 
Monocalcium 
phosphate 
anhydrous 
(MCPA) 
Ca(H2PO4)2 0.5 Stable at T 
>100°C 
 
Dicalcium 
phosphate 
dihydrate 
(DCPD) 
Ca(HPO4).2H2O 1.0 2.0 – 6.0 Biocompatible, 
biodegradable and 
osteoconductive 
Dicalcium 
phosphate 
anhydrous 
(DCPA) 
Ca(HPO4) 1.0 Stable at T 
>100°C 
 
Octacalcium 
phosphate 
(OCP) 
Ca8(HPO4)2(PO4)
4.5H2O 
1.33 5.5 – 7.0 Metastable precursor 
of CaPs that 
transforms into HA 
Amorphous 
calcium 
phosphate 
(ACP) 
CaxHy(PO4)z.nH2
O 
(n = 3 - 4.5) 
1.2 - 2.2 ~ 5 – 12 
(Always 
metastable) 
Lacks long range 
order 
Calcium-
deficient 
hydroxyapatite 
(CDHA) 
Ca9(HPO4)(PO4)5
(OH) 
1.5 – 1.67 6.5 – 9.5 
Poorly crystalline 
β-Tricalcium 
phosphate (β-
TCP) 
β-Ca3(PO4)2 1.5 Cannot be 
precipitated 
from 
aqueous 
solutions 
Biodegradable 
α-Tricalcium 
phosphate (α-
TCP) 
α-Ca3(PO4)2 1.5 Cannot be 
precipitated 
from 
aqueous 
solutions 
 
  
Attention in the biomedical field is generally focused on HA, α- and β-TCP, CDHA and biphasic 
CaPs, since implants made of calcined HA stay in bone defects for many years upon implantation 
(56, 62). HA is crystalline and is the most stable and least soluble CaPs in an aqueous solution 
below pH 4.2 (56). HA can be produced using wet methods, such as precipitation method, 
hydrothermal synthesis and solid-state reaction of, for example, MCPM, DCPA, DCPD, OCP, 
above 1200ºC (63-66). β-TCP is a high temperature phase of CaPs, obtained by thermal 
decomposition at temperatures above 800ºC. β-TCP is biodegradable and has been extensively 
used as bone substitute, either as granules or blocks, or even in CaPs-based bone cements (57). It 
has been reported that the biological resorption capability of HA and β-TCP is different though 
their similarity in terms of chemical composition. HA has a slow resorption rate and may remain 
integrated into the regenerated bone tissue after implantation, whereas β-TCP is completely 
reabsorbed (67, 68). Therefore, clinical applications have been performed using the biphasic CaPs, 
as a result of combining HA and β-TCP, thus improving the bioresorbability and strength of the 
bone substitutes (62, 66, 69). α-TCP is usually prepared from β-TCP phase at heat treatment above 
1125ºC, and quenching it prevents the reverse transformation (70). α-TCP is biocompatible, and 
more biodegradable and reactive than β-TCP (71). CDHA is obtained by precipitation in an 
aqueous solution above a pH 7 (56). Their crystals are in general poorly crystalline and of 
submicron dimensions. The solubility of CDHA increases with a decrease of Ca/P molar ratio, 
crystallinity and size. CDHA can decompose into β-TCP, into a mixture of HA and β-TCP or into 
pure HA, when heating above 700ºC (62, 72). As a first approximation, CDHA may be considered 
as HA with some ions missing (73).  
 
 
4.2.3.1 Calcium phosphates-based cements 
 
In 1832, Ostermann prepared a CaP biomaterial in the form of a paste that set in situ to form a 
solid material. Nevertheless, Brown and Chow in 1986 (74) were the first to present this new form 
of CaPs, currently known as calcium phosphate-based cements (CPCs). 
CPCs result from the mixture of one or several CaPs and an aqueous solution, which then 
precipitate into a less soluble CaP and sets by the entanglement of the growing crystals, providing 
mechanical stiffness to the cement, and then, the paste can be placed into the bone defect (Figure 
4). Subsequently it hardens in situ, at body temperature, and then displays limited solubility.  
Hydroxyapatit
e (HA) 
Ca10(PO4)6(OH)2 1.67 9.5 – 12 Osteoconductive 
Tetracalcium 
phosphate 
(TTCP) 
Ca4(PO4)2O 2.0 Cannot be 
precipitated 
from 
aqueous 
solutions 
Biocompatible but 
poorly biodegradable 
CPCs salient features are excellent biocompatibility and resorbability, bioactivity, non-
cytotoxicity, development of osteoconductive pathways and sufficient compressive strength for a 
number of applications (56, 67, 75, 76). CPCs are mechanically much stronger in compression 
than in tension or shear, because entangled crystals are not well bonded. Compressive strength 
values are typically 5–10 times larger than that of tensile strength. The foremost advantages of the 
CPCs include fast setting, excellent mouldability and manipulation. Hence, these bioceramics are 
commonly used to fill bone defects and trauma surgeries as mouldable paste-like bone substitute 
materials. Besides, like any other bioceramics, CPCs provide the opportunity for bone grafting 
using alloplastic materials, which are unlimited in quantity and provide no risk of infectious 
diseases. 
CPCs can be classified according to their end product into apatite (AP) cements and dicalcium 
phosphate dehydrate (DCPD or brushite) cements, upon the pH value of a cement paste after 
setting. AP is formed above pH 4.2, whereas brushite is preferentially formed when pH value of 
the paste is < 4.2, although it may grow even up to pH 6.5, due to kinetics reasons (77, 78). Brushite 
cements have raised interest due to their higher solubility and resorbability in vivo much faster 
than AP cements. Although AP cements show higher mechanical strength, they have slow in vivo 
resorption rates that interfere with the bone regeneration process (79, 80). Moreover, brushite-
based cements possess faster setting reactions (19, 81).  
 
 
 
 
FIGURE 4. A) Self-setting CPCs pastes resultant from CaPs powders and an aqueous solution 
that then can be injected into the bone defect; and B) Brushite cement microstructure after 
hardening, showing entangled growing crystals, which provides the mechanical stiffness to the 
cement (82, 83). Reprinted from Ref.(83), with permission. 
  
 
4.3 BIOCERAMICS APPLICATIONS IN TISSUE ENGINEERING 
A diversity of clinical procedures using bioceramics include bone grafting, drug delivery, gene 
transfection, and for bone cancer treatment (84-86). Alongside is the possibility to combine them 
with bioactive signaling molecules and/or stem cells that provide important cues and signals 
promoting cells adhesion, proliferation, differentiation, and metabolic activity for the in vivo 
regeneration process. These bioactive molecules encompass growth factors (with proliferation-
inducing effects), mitogens (that stimulate cell division), and morphogens (that control generation 
of tissue form). Bone morphogenetic proteins (BMPs) growth factors are the most significantly 
used for bone growth and healing, namely in spinal fusion, long bone defects, and oral and 
maxillofacial surgery, due to their osteoinduction ability (87, 88). Stem cells (human MSCs, 
human bone marrow stromal cells (hBMSCs), human endometrial stem cells, adipose-derived stem 
cells) have promising outcome of functional bone recovery, with good implant integration and host 
bone formation post-surgery (89). For instance, an interesting recent study reported that CPC-
based scaffold combining mesoporous silica with recombinant human BMP-2 (rhBMP-2) might 
provide a solution to issues of tissue necrosis during the regeneration process by facilitating 
vascularization and osteogenesis (90). The scaffolds induced the osteogenic differentiation of 
hBMSCs and demonstrated abundant new vessel formation, as well as rapid rates of osteogenesis 
in vivo owing to the collaborative effects of the biomaterials and growth factor.  
Currently there is a range of ceramic products made of alumina/zirconia, bioactive glass and glass-
ceramics, and CaPs-based implants as porous and fibrous scaffolds, and hydrogels (60, 91, 92). 
For instance, Oliveira et al. (93) prepared porous HA scaffolds with highly interconnectivity, using 
an organic sacrifice template, for bone TE (Figure 5). In vitro cell/material interaction tests using 
rat bone marrow stromal cells (RBMSCs) demonstrated that the cells adhered, proliferated well 
and remained viable on the scaffolds. 
 
 
 
FIGURE 5. HA porous scaffold: (a) macroscopic image, (b) microstructure, (c) microstructure 
after immersion in SBF for 7 days showing the ‘‘cauliflower like’’ morphology of apatite formed 
on the scaffold surface, and microstructure showing RBMSCs seeded after culturing for (d) 24 h 
and (e) 7 days (scale bar: 10 m). Reprinted from Ref. (93), with permission. 
 
 
Mainly of these bioceramic implants are used in non-load-bearing applications, or compressive 
load situations, owing to their biomechanical limitations, namely as bone fillers of defects in 
reconstruction surgery, middle ear repair, vertebral, and iliac crest replacements (57, 58, 94). 
However, bioceramics-based composite scaffolds have appear as an alternative to circumvent this 
drawback and to be used to engineer hard tissues. An example is the production of CaPs-based 
composite scaffolds showing worthy mechanical properties and stability, and self-mineralization 
capability without cytotoxicity for bone TE (4, 93). Our group has been proposed composite 
porous scaffolds using CaPs and biodegradable and biopolymeric matrices (i.e., proteins, 
polysaccharides, and glycosaminoglycans) as a strategy for TE and regeneration (4, 6, 7, 95). For 
example, silk fibroin/nanosized CaPs composite scaffold provided an optimal microenvironment 
in terms of porosity and pore interconnectivity, and physicochemical structure, with self-
mineralization capability and no cytotoxicity (Figure 6) (4, 96). Further, the incorporation of CaP 
in the silk fibroin matrix promoted the attachment, viability, and proliferation of the hASCs (96).  
 
 
 
 FIGURE 6. Silk fibroin/CaPs composite scaffolds: (a) 3D Micro-CT image showing CaP (white 
region) and silk fibroin matrix (gray region), (b) microstructure, and (c)-(e) H&E staining of 
hASCs cultured on the scaffolds for 3, 7, and 14 days, respectively. Scale bar: 500 mm. Reprinted 
from Ref.(96), with permission. 
 
 
Extensive studies have also reported bioactive glass ceramic-based composites for the regeneration 
of hard and soft tissues. For instance, it was shown that a porous tri-layered nanocomposite 
scaffold composed of chitin poly (lactic-co-glycolic acid)/nano bioactive glass ceramic/cementum 
protein 1 as the cementum layer, chitin- poly (lactic-co-glycolic acid)/fibroblast growth factor 2 as 
the periodontal layer, and chitin- poly (lactic-co-glycolic acid)/nano bioactive glass 
ceramic/platelet-rich plasma derived growth factors as the alveolar bone layer, is cytocompatible 
and favored cementogenic, fibrogenic, and osteogenic differentiation of human dental follicle stem 
cells (97). The scaffold with growth factors demonstrates complete defect closure and healing with 
new cancellous-like tissue formation and formation of new cementum, fibrous periodontal tissue, 
and alveolar bone with well-defined bony trabeculae in comparison to the other three groups, upon 
implantation into rabbit maxillary periodontal defects. Gantar et al. (98) prepared gellan-gum 
hydrogels reinforced with bioglass to improve the microstructure and the mechanical properties of 
the biomaterial for bone TE. The hydrogels exhibited an open and well-interconnected porosity of 
~80 % and a pore size of ~100-200 m, recommended for bone TE scaffolding. Moreover, the 
ions released from the bioglass conferred the possibility to mineralize in vitro when combined with 
adipose stem cells. 
An overview of bioceramics for varied TE purposes are summarized in Table 1.2.  
 
 
TABLE 1.2 Summary of bioceramics in different TE applications. 
Application Bioceramic materials Function References 
Maxillofacial surgery Bioglass®, HA and β-
TCP scaffolds, biphasic 
CaPs; self-setting CPCs 
 
Repair/replacement of lost teeth;  
filling of jaws defects; 
reconstruction of mandible and 
temporomandibular joint 
 
(94, 99) 
 
Orbital surgery 
 
Alumina, HA, 
Bioglass 
 
Improving prosthesis motility 
resulting in a very natural-
appearing eye; orbital floor 
fractures repair 
 
(100, 101) 
Dental surgery 
 
Alumina, zirconia, 
bioglass, HA 
Replace diseased, damaged or 
loosened teeth 
 
(102) 
Periodontal 
regeneration 
Alumina, zirconia, HA 
and β-TCP 
nanoparticles, and 
bioactive glasses 
 
Promote enamel, dentin and 
periodontium healing; 
differentiation and proliferation 
of ameloblasts, odontoblasts, 
cementoblasts, osteoblasts and 
fibroblasts 
 
(88, 103) 
 
Lung tissue engineering 
 
Bioglass composite Adhesion and proliferation of 
human lung epithelial type II 
cells 
 
(104) 
Joint arthroplasty 
 
Alumina, zirconia, 
bioglasses and HA 
coatings of acetabular 
cup 
Osteoconduction and 
osteointegration of prosthetic 
devices; To reduce wear and 
inflammatory response 
 
(105) 
Bone defects and 
diseases 
 
Bioglass, CaPs, and 
CPCs 
 
Filling bone defects; Repair and 
regeneration of damaged bone 
(25, 53, 106) 
Spinal surgery Zirconia, bioglass, and 
CPCs 
Immobilize vertebrae to protect 
spinal cord; high compressive 
strength 
 
(107, 108) 
Wound healing Silver doped bioactive 
glass, Bioglass 
Bioactive, antimicrobial and 
bactericidal properties to the 
sutures 
(109) 
Cosmetics Bioglass (Vitryxx®, 
Schott AG) 
 
Antiaging benefits, such as 
reducing redness and wrinkles 
(110) 
 
 
4.4 CLINICAL TRIALS  
Human clinical research studies conducted around the world are designed to answer specific 
questions about biomedical or behavioral interventions, including new treatments and known 
interventions that warrant further study and comparison. Clinical trials give data on products safety 
and efficacy and are only conducted after approval of the health ethics committee. Table 1.3 
provides the completed and ongoing (with no reported results so far) clinical research trials for TE 
applications using different types of bioceramics.  
The process of the products commercialization for implantation involves multiple stages of R&D 
replications before reaching the final stages of approval from the governing bodies. R&D stages 
ensure efficacy and safety of the devices, involving the fabrication of medical grade scaffolds 
followed by animal testing under regulatory approved conditions. The FDA provides regulatory 
guidance and approval for biomaterials and devices and classified them according the associated 
risk. Fracture fixation devices are classified as Class 2 - medium risk, while devices for organs 
replacement, such as heart valves, are Class 3 (111). 
Up to now, for bone regeneration there are no tissue engineered approaches fully approved for 
clinical application. Instead, just engineered materials/scaffolds already regulatory approved are 
arriving in the clinic as bone grafts (without the combination of cells), such as Infuse® Bone Graft 
(Medtronic Sofamor Danek) used for fusion of spinal cage, Osigraft (Stryker Biotech) for long 
bone non-unions applications, and Grafton® Orthoblend (OsteoTech) as a bone void filler for small 
and large defects, have been successfully reported. Despite their efficacy in bone regeneration, 
clinical translation of scaffold-based bone therapies is limited to small defects due to insufficient 
mechanical integrity.  
A remarkable and largest commercial is the use of bioactive glass in toothpastes. A bioglass 45S5 
particulate, named NovaMin® (NovaMin Technology, FL, owned by GlaxoSmithKline, UK since 
2010) and fluoride-releasing bioactive glass, denominated BioMinF® (BioMin Technologies Ltd, 
London, UK) were designed to promote a partial remineralization of a demineralized enamel, as 
well as, a whitening effect and reduce tooth sensitivity (110, 112).  
 
 
TABLE 1.3 List of completed and ongoing clinical trials using bioceramics for TE applications. Information obtained 
from https://clinicaltrials.gov/. 
NCT number 
Date and 
status 
Study 
Patients 
age 
Follow-up Procedure 
NCT00200603 
2005 
 
Autograft Versus Calcium 
Phosphate Macroporous 
Bioceramics as Bone 
Substitute for Tibial 
Valgus Osteotomy 
Adult 
and 
senior 
n.d. Tibial valgus osteotomy 
NCT00900718 
2006-2008 
Conpleted 
Comparison of Straumann 
Bone Ceramic and Bio-
Oss in Combination With 
Guided Tissue 
Regeneration for Volume 
Preservation of Alveolar 
Ridge After Tooth 
Extraction 
18-75 yrs n.d. Bone augmentation 
NCT01147315 
2009-2016 
Completed 
Prospective Study of 
Hybrid Bone Substitution 
With Calcium-phosphate 
Ceramic Biomaterial and 
Autologous Bone Marrow 
18-75 yrs n.d. Hybrid bone substitution 
for Mandibular 
Osteoradionecrosis 
Treatment 
NCT01813188 
2011-2014 
Completed 
(Phase 2) 
Non-inferiority and lower 
morbidity of the use of 
bone marrow 
mononuclear cells seeded 
onto a porous matrix of 
calcium phosphate, for the 
consolidation of tibial 
bone defects 
(pseudoarthrosis), 
compared with autologous 
bone graft 
18-75 yrs 6 mths 
Autologous bone marrow 
cells seeded onto a 
porous tricalcium 
phosphate ceramic and 
demineralized bone 
matrix 
NCT01282034 
2011-2016 
Completed 
Multicenter Randomized 
Controlled Trial for the 
Treatment of Knee 
Chondral and 
Osteochondral Lesions: 
Marrow Stimulation 
Techniques vs MaioRegen 
18-60 yrs 24 mths 
Marrow stimulation - 
Drilling or Microfractures 
 
NCT01824706 
2012-2016 
Completed 
 
A Prospective, 
Multicenter Observational 
Study Evaluating the Long 
Term Safety in Terms of 
Explantation Rate and 
Number of Infections of 
the Custom-made 
Bioceramic Implant 
CustomBone™ 
Child, 
adult, 
and 
senior 
2 yrs Craniectomy 
NCT02389569 
2016 
Completed 
Clinical Study of 
Biosilicate Under Resin 
Composite Restorations in 
Caries Affected Teeth 
18-45 yrs 18 mths Dental caries 
NCT00841152 2009-2018 
Comparison of two 
synthetic ceramic bone 
graft substitutes, bioactive 
glass and beta-tricalcium 
phosphate, in filling of 
contained bone defects 
following surgical 
evacuation of benign bone 
tumor or tumor-like 
conditions. 
Adult 
and 
senior 
12 mths 
Hand and long-bone 
defects filling 
NCT01742260 
2013-2017 
Phase 1 
A Pilot Study to 
Demonstrate Safety and 
Feasibility of Cranial 
Reconstruction Using 
Mesenchymal Stromal 
Cells and Resorbable 
Biomaterials 
18-80 yrs n.d. 
Repair of cranial defects 
by tissue engineering 
NCT01771302 2013-2015 
Efficiency of plasma rich 
in growth factors in 
combination with bone 
grafts in the healing of 
bone and soft tissues in 
lateral sinus floor 
elevation 
Adult 
and 
senior 
6 mths Bone healing 
NCT02910232 
2014-2016 
Phase 3 
In Vivo Clinical Trial of 
Porous Starch - 
Hydroxyapatite 
Composite Biomaterials 
for Bone Regeneration 
20-60 yrs 6 mths 
Bone void filler of foot 
fracture 
NCT01974362 2016-2017 
Monolithic Zirconia Full-
Mouth Implant Supported 
Rehabilitation Behavior 
Adult 
and 
senior 
12 mths 
Place dental implants in 
both jaws (maxilla and 
mandible) according to 
manufacturer 
specifications 
n.d.: not defined 
 
 
4.5 CONCLUDING REMARKS AND FUTURE OUTLOOK 
Bioceramics have been used very successfully within the human body by repairing and 
regenerating bone faster that would not restore by other means. These biomaterials are commonly 
used in orthopedic and dental surgery, but they are potentially suitable for a wide range of essential 
TE applications. TE has much to bring in respect to combining biomaterials, growth 
factors/bioactive molecules and cells. Innovative strategies present some of the current challenges 
in the field, and may constitute major breakthroughs in the future. Bioceramics offer desirable 
characteristics such as biocompatibility, chemical inertness in biological mediums and hardness, 
but they have low resistance to traction. Ongoing research involves the chemistry, composition, 
and micro- and nanostructure of the materials to improve the mechanical integrity of the 
bioceramics upon implantation, and appropriate porosity for the cellular adhesion, proliferation 
and differentiation. Biomimetic strategies designed for TE scaffolding have been concentrated on 
3D-based porous and dense scaffolds and fibres, and hydrogels. The latter ones are of particular 
interest due to their high water content, besides biodegradability and biocompatibility. Although 
there have been significant advances in engineer new tissues, future developments in order to 
achieve major improvements should be focused and turn them into a clinically viable strategy. 
Strategies should be devoted on the clear understanding of the bioceramics-tissue interactions, and 
hierarchical structure for long-term service, and the related mechanical strength, especially the 
fatigue limit under periodic external stress.  
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